Investigating how GTP levels affect melanoma cell invasion and spread
The role of regulation and subcellular localization of GTP biosynthesis in melanoma invasion and metastasis
This study is looking at how melanoma cells spread to the brain and is exploring a specific protein that helps these cells move, with the hope of finding new ways to stop or slow down this aggressive cancer, which could lead to better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10916181 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms that allow melanoma cells to invade and metastasize, particularly to the brain. It examines the role of RHO-GTPases, specifically RAC1, in regulating cell movement and how local levels of GTP influence these processes. By studying these cellular dynamics, the research aims to uncover new therapeutic targets that could potentially halt or reverse the progression of metastatic melanoma. Patients may benefit from insights that could lead to innovative treatments for this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic melanoma, particularly those with brain metastases.
Not a fit: Patients with non-melanoma skin cancers or those without metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve survival rates for patients with metastatic melanoma.
How similar studies have performed: Previous studies have shown promising results in targeting RHO-GTPases in cancer treatment, suggesting that this approach may lead to significant advancements.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Nikiforov, Mikhail — Duke University
- Study coordinator: Nikiforov, Mikhail
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.